Abstract
Cryopyrinopathies are a group of rare autoinflammatory diseases that includes familial cold autoinflammatory syndrome, Muckle–Wells syndrome and chronic infantile neurologic cutaneous articular syndrome (also termed neonatal-onset multisystemic inflammatory disease). These syndromes were initially considered to be distinct disease entities despite some clinical similarities; however, mutations of the same gene have since been found in all three cryopyrinopathies. These diseases, therefore, are not separate but represent a continuum of subphenotypes. The gene in question, CIAS1 (now renamed NLRP3) encodes NALP3 (also known as cryopyrin). NALP3 is an important mediator of inflammation and interleukin 1β processing. New therapies based on biologic agents that specifically target interleukin 1β are currently being developed. These new agents have provided very encouraging results for patients with these long-lasting inflammatory conditions—which used to be considered refractory to treatment. The development of therapeutic options for these cryopyrinopathies illustrates effective translation of basic science to clinical practice and the convergence of human genetics and targeted therapies.
Key Points
-
The autoinflammatory conditions FCAS, MWS and CINCA (NOMID) are autosomal-dominant or sporadic syndromes that represent a continuum of subphenotypes (FCAS is the mildest condition, CINCA/NOMID the most severe)
-
FCAS, MWS and CINCA (NOMID) are caused by mutations of the same gene, CIAS1 (now termed NLRP3), which encodes NALP3, also known as cryopyrin, an important mediator of inflammation and interleukin 1β processing
-
Promising new therapies based on biologic agents that target interleukin 1β, are currently under investigation for the treatment of patients with these cryopyrinopathies
-
Treatment of CINCA (NOMID) is more complex than that of other cryopyrinopathies because patients with CINCA (NOMID) have severe disease and the broadest range of symptoms
-
The potential risk of serious infections during treatment with interleukin 1 antagonists has to be considered, especially in the pediatric population; this risk may be exacerbated by use of high-affinity, long-acting molecules
-
The development of therapeutic options for these cryopyrinopathies illustrates the effective translation of basic science to clinical practice and the convergence of human genetics and targeted therapy
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Stojanov S and Kastner DL (2005) Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 17: 586–599
Kile RL and Rusk HA (1940) A case of cold urticaria with an unusual familial history. JAMA 114: 1067–1068
Hoffman HM et al. (2001) Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 108: 615–620
Hoffman HM et al. (2003) Fine structure mapping of CIAS1: identification of an ancestral haplotype and a common FCAS mutation, L353P. Hum Genet 112: 209–216
Johnstone RF et al. (2003) A large kindred with familial cold autoinflammatory syndrome. Ann Allergy Asthma Immunol 90: 233–237
Muckle TJ et al. (1962) Urticaria, deafness and amyloidosis: a new heredo-familial syndrome. Q J Med 122: 235–248
Watts RA et al. (1994) The arthropathy of the Muckle–Wells syndrome. Br J Rheumatol 33: 1184–1187
Lequerre T et al. (2007) A cryopyrin-associated periodic syndrome with joint destruction. Rheumatology (Oxford) 46: 709–714
Prost A et al. (1976) Intermittent rheumatism revealing a familial syndrome. Arthritis—urticarian eruptions—deafness: Muckle–Wells syndrome without kidney amylosis [French]. Rev Rhum Mal Osteoartic 43: 201–208
Hawkins PN et al. (2004) Spectrum of clinical features in Muckle–Wells syndrome and response to anakinra. Arthritis Rheum 50: 607–612
Prieur AM and Griscelli C (1980) Chronic meningo-cutaneo-articular syndrome in children [French]. Rev Rhum Mal Osteoartic 47: 645–649
Prieur AM and Griscelli C (1981) Arthropathy with rash, chronic meningitis, eye lesions, and mental retardation. J Pediatr 99: 79–83
Hill SC et al. (2007) Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). Pediatr Radiol 37: 145–152
Dollfus H et al. (2000) Chronic infantile neurological cutaneous and articular/neonatal onset multisystem inflammatory disease syndrome: ocular manifestations in a recently recognized chronic inflammatory disease of childhood. Arch Ophthalmol 118: 1386–1392
Prieur AM et al. (1987) A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl 66: 57–68
Torbiak RP et al. (1989) NOMID—a neonatal syndrome of multisystem inflammation. Skeletal Radiol 18: 359–364
Prieur AM (2001) A recently recognised chronic inflammatory disease of early onset characterised by the triad of rash, central nervous system involvement and arthropathy. Clin Exp Rheumatol 19: 103–106
Neven B et al. (2004) Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU. Blood 103: 2809–2815
Granel B et al. (2005) Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome. Rheumatology (Oxford) 44: 689–690
Hentgen V et al. (2005) Intrafamilial variable phenotypic expression of a CIAS1 mutation: from Muckle–Wells to chronic infantile neurological cutaneous and articular syndrome. J Rheumatol 32: 747–751
Hoffman HM et al. (2001) Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome. Nat Genet 29: 301–305
Feldmann J et al. (2002) Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 71: 198–203
Ting JP et al. (2006) CATERPILLERs, pyrin and hereditary immunological disorders. Nat Rev Immunol 6: 183–195
Fritz JH and Girardin SE (2005) How Toll-like receptors and Nod-like receptors contribute to innate immunity in mammals. J Endotoxin Res 11: 390–394
Fritz JH (2006) Nod-like proteins in immunity, inflammation and disease. Nat Immunol 7: 1250–1257
Manji GA et al. (2002) PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NFκB. J Biol Chem 277: 11570–11575
Martinon F (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol Cell 10: 417–426
Martinon F et al. (2004) Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr Biol 14: 1929–1934
Kanneganti TD et al. (2006) Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/NALP3. Nature 440: 233–236
Kanneganti TD et al. (2006) Critical role for cryopyrin/NALP3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J Biol Chem 281: 36560–36568
Jesus AA et al. (2007) Phenotype–genotype analysis of cryopyrin-associated periodic syndromes (CAPS): description of a rare non-exon 3 and a novel CIAS1 missense mutation. J Clin Immunol 28: 134–138
Mariathasan S et al. (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440: 228–232
Martinon F et al. (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237–241
Feldmeyer L et al. (2007) The inflammasome mediates UVB-induced activation and secretion of interleukin-1β by keratinocytes. Curr Biol 17: 1140–1145
Petrilli V et al. (2007) Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 14: 1583–1589
Yu JW et al. (2006) Cryopyrin and pyrin activate caspase-1, but not NFκB, via ASC oligomerization. Cell Death Differ 13: 236–249
Dowds TA et al. (2004). Cryopyrin-induced interleukin 1β secretion in monocytic cells: enhanced activity of disease-associated mutants and requirement for ASC. J Biol Chem 279: 21924–21928
Agostini L et al. (2004) NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle–Wells autoinflammatory disorder. Immunity 20: 319–325
Frenkel J et al. (2004). Variant chronic infantile neurologic, cutaneous, articular syndrome due to a mutation within the leucine-rich repeat domain of CIAS1. Arthritis Rheum 50: 2719–2720
Matsubayashi T et al. (2006) Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the CIAS1 gene. Acta Paediatr 95: 246–249
Jeru I et al. (2006) PYPAF1 nonsense mutation in a patient with an unusual autoinflammatory syndrome: role of PYPAF1 in inflammation. Arthritis Rheum 54: 508–514
Aksentijevich I et al. (2007) The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 56: 1273–1285
Saito M et al. (2005) Somatic mosaicism of CIAS1 in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 52: 3579–3585
Saito M et al. (2007) Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patients. Blood 111: 2132–2141
Kallinich T (2005) The clinical course of a child with CINCA/NOMID syndrome improved during and after treatment with thalidomide. Scand J Rheumatol 34: 246–249
Fleischmann RM et al. (2003) Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1RA), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 48: 927–934
Schiff MH et al. (2004) The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum 50: 1752–1760
Hawkins PN et al. (2003) Interleukin-1-receptor antagonist in the Muckle–Wells syndrome. N Engl J Med 348: 2583–2584
Hoffman HM et al. (2004) Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364: 1779–1785
O'Connell SM et al. (2007) Response to IL-1-receptor antagonist in a child with familial cold autoinflammatory syndrome. Pediatr Dermatol 24: 85–89
Rynne M et al. (2006) Hearing improvement in a patient with variant Muckle–Wells syndrome in response to interleukin 1 receptor antagonism. Ann Rheum Dis 65: 533–534
Mirault T et al. (2006) Recovery from deafness in a patient with Muckle–Wells syndrome treated with anakinra. Arthritis Rheum 54: 1697–1700
Dalgic B et al. (2007) A variant Muckle–Wells syndrome with a novel mutation in CIAS1 gene responding to anakinra. Pediatr Nephrol 22: 1391–1394
Leslie KS et al. (2006) Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 142: 1591–1597
Thornton BD et al. (2007) Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist. Am J Kidney Dis 49: 477–481
Frenkel J et al. (2004) Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al. and Hoffman and Patel. Arthritis Rheum 50: 3738–3739
Lovell DJ et al. (2005) Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 52: 1283–1286
Goldbach-Mansky R et al. (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med 355: 581–592
Hoffman H et al. (2008) Rilonacept in patients with cryopyrin-associated periodic syndromes (CAPS): the durability of symptoms over 48 weeks. Presented at the Fifth International Congress on FMF and Systemic Autoinflammatory Diseases: 2008 April 4–8, Rome, Italy
Kuemmerle-Deschner JB et al. (2008) Long-lasting response to ACZ885 (a new human IgG1 anti IL-1beta monoclonal antibody) in patients with Muckle-Wells syndrome (MWS). Presented at the Fifth International Congress on FMF and Systemic Autoinflammatory Diseases: 2008 April 4–8, Rome, Italy
Lachmann H et al. Treatment of cryopyrin associated periodic syndrome with a fully human anti IL-1beta monoclonal antiboby (ACZ885): results from a subcutaneous administration study. Presented at the Fifth International Congress on FMF and Systemic Autoinflammatory Diseases: 2008 April 4–8, Rome, Italy
Stack JH et al. (2005) IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol 175: 2630–2634
Lachmann H et al. (2005) An orally active ICE/Caspase-1 inhibitor, VX-765, reduces inflammatory biomarkers and symptoms in patients with Muckle–Wells symptoms. Presented at the Fourth International Congress on the Systemic Autoinflammatory Diseases, “FMF and Beyond”: 2005 November 6–10, Bethesda, MD, USA
Jeru I et al. (2008) Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci USA 105: 1614–1619
Acknowledgements
Désirée Lie, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the Medscape-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Neven, B., Prieur, AM. & dit Maire, P. Cryopyrinopathies: update on pathogenesis and treatment. Nat Rev Rheumatol 4, 481–489 (2008). https://doi.org/10.1038/ncprheum0874
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0874
This article is cited by
-
The everchanging framework of autoinflammation
Internal and Emergency Medicine (2021)
-
Autoinflammatory diseases in childhood, part 1: monogenic syndromes
Pediatric Radiology (2020)
-
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
Nature Communications (2020)
-
Polymorphisms and expression of inflammasome genes are associated with the development and severity of rheumatoid arthritis in Brazilian patients
Inflammation Research (2018)
-
Interleukin-1 as a mediator of fatigue in disease: a narrative review
Journal of Neuroinflammation (2017)